ABBV-CLS-7262 is an eIF2B activator being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Calico is responsible for research and early development and will advance collaboration projects into Phase 2a, including ABBV-CLS-7262. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities.
Type of MoleculeSmall Molecule
Product TypeNew Indication
|Potential Indication||Region||Phase (1, 2, 3, Submitted)|
|Amyotrophic Lateral Sclerosis (ALS)||n/a||